很多人体检往往检查同样的几个基础项目，其实，不同年龄段体检侧重点截然不同。不同年龄段体 检"必查项"有哪些？ 30—40岁人群 "三高"是体检重点 30岁后人体各项机能虽处于巅峰状态，但这个年龄段的人普遍工作压力大、应酬多，饮食习惯不科学以 及运动量不足，容易发胖。这一时期要重点关注血压、血糖和血脂变化，若有异常需马上调整。 专家建议： 每半年检查一次血压、血糖和血脂，肥胖人群则每3个月检查一次。 女性重点关注妇科检查、乳腺检查项目。 男性35岁以后，每1至2年增加前列腺检查。 40—50岁人群 心血管、肿瘤是体检重点 40—50岁年龄段是"健康高危期"，心血管疾病风险增加，必须关注心脏问题；同时，这个年龄段，癌症 发病逐渐增多。 专家建议： 心脏彩超、心电图等检查不可少。 肺部CT不可少，可筛查肺癌。 女性重点关注乳腺及妇科疾病，乳腺超声或钼靶检查筛查乳腺癌，人乳头瘤病毒（HPV）检测加上宫颈 细胞学检查筛查宫颈癌。 男性重点关注胃肠疾病，可根据需要选择做胃肠镜，筛查胃癌、结直肠癌等。 50岁以上人群 骨密度、血管是体检重点 50岁开始，人体机能衰退，尤其是女性骨质疏松高发。如果出现浑身疼痛、容易骨折等症状 ...

Core Viewpoint - The company, Rendu Biotech, reported a decline in revenue and net profit for the first half of 2025, but is focusing on technological innovation and international expansion to drive long-term growth [2][3][4]. Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% [2]. - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% year-on-year [2]. - Despite challenges, the company saw over 50% year-on-year growth in sales of certain blood test products, particularly in the hepatitis B sector [2]. R&D and Innovation - The company has developed a new technology platform called "Digital SAT + Automatic Supporting Equipment DigiNAT," which offers significant advantages over traditional digital PCR technology [3]. - The company is focusing on RNA digital precision quantitative detection products, particularly in cancer screening and diagnosis, with ongoing development of prostate and bladder cancer tests [3]. - The global liquid biopsy market is expected to grow at a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments [3]. International Expansion - The company has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India [4]. - The company’s chlamydia (CT) and human papillomavirus (HPV) test kits received IVDR CE certification from a European Union notified body, allowing entry into the EU market [4]. - The certification highlights the company's strengths in product development and regulatory compliance, positioning it well for future international registrations [4].

Core Viewpoint - The importance of personalized health check-up plans is emphasized, highlighting that a one-size-fits-all approach is inadequate for effectively identifying health issues [1][2]. Group 1: Health Check-up and Cancer Detection - Health check-ups should be tailored to individual needs, taking into account personal medical history, lifestyle, and family history to optimize the detection of potential health issues [1][2]. - Certain cancers, such as breast, cervical, lung, colorectal, and prostate cancers, have shown significant benefits from screening through health check-ups, while other malignancies still lack comprehensive screening methods [2][3]. - The effectiveness of cancer detection through health check-ups depends on the characteristics of the cancer, the medical methods used, and the technology applied [3]. Group 2: Importance of Regular Monitoring - Regular health check-ups serve as a crucial tool for early detection of diseases, allowing for the assessment of overall health and identification of chronic disease risks [3]. - Screening results should be viewed as clues or risk indicators rather than definitive diagnoses, necessitating further specialized tests for confirmation [3]. - Continuous monitoring of health status is vital, as annual check-ups help establish a personal health baseline, making it easier to detect changes over time [3].

Core Viewpoint - The company, Kehua Bio-Engineering (002022), is leveraging its immune technology platform to develop tumor marker detection reagents for early screening and auxiliary diagnosis of cancers such as liver, stomach, and lung cancers [1] Group 1: Product Development - The company has developed tumor marker detection reagents that can be used in conjunction with its universal detection instruments for early cancer screening and auxiliary diagnosis [1] - A subsidiary, Tianlong, has developed products based on fluorescence PCR technology that assist in cancer screening, including HPV detection kits for cervical cancer and EB virus detection kits for nasopharyngeal cancer [1]